News

Bacteremic sepsis in ALL tied to neurocognitive dysfunction


 

Photo by Bill Branson

Child with leukemia

Bacteremic sepsis during acute lymphoblastic leukemia (ALL) treatment may contribute to neurocognitive dysfunction later in life, results of a cohort study suggest.

Pediatric ALL survivors who had sepsis while on treatment performed worse on measures of intelligence, attention, executive function, and processing speed than survivors with no sepsis history, according to study results.

Links between sepsis and impaired neurocognitive function found in this study have “practice-changing implications” for cancer survivors, investigators reported in JAMA Pediatrics.

“Prevention of infection, early recognition and appropriate management of sepsis, and preemptive neurocognitive interventions should be prioritized, because these might prevent or ameliorate neurologic damage,” said Joshua Wolf, MBBS, of St. Jude Children’s Research Hospital, Memphis, and the coauthors of the report.

The study included 212 children who, at a median age of 5 years, had received risk-adapted chemotherapy for ALL with no hematopoietic cell transplant or cranial irradiation.

Sixteen of the patients (7.5%) had a history of bacteremic sepsis during ALL therapy, according to retrospectively obtained data.

As a part of the study, all patients participated in neurocognitive testing, which was done at a median of 7.7 years after diagnosis.

Patients with a history of bacteremic sepsis performed poorly on multiple measures of neurocognitive function, as compared with all other patients, according to results of analyses that were adjusted for multiple potentially confounding factors, such as age, race, and leukemia risk category.

Although not all neurocognitive measures were significantly different between groups, survivors with a sepsis history performed worse on evaluations of spatial planning (difference, 0.78; 95% CI, 0.57-1.00), verbal fluency (0.38; 95% CI, 0.14-0.62), and attention (0.63; 95% CI, 0.30-0.95), among other measures.

This is believed to be the first published study looking at potential links between sepsis during ALL treatment and long-term neurocognitive dysfunction, investigators said. However, similar observations have been made in other patient populations, they added.

Exactly how sepsis might lead to neurocognitive deficits remains unclear.

“In the population of children with cancer, these mechanisms might be augmented by increased blood-brain barrier permeability to neurotoxic chemotherapy drugs,” the investigators said in their report.

Further study is needed to look at potential brain injury mechanisms and to validate the current findings in other ALL patient cohorts, they concluded.

The study was supported by the National Institute of Mental Health, the National Cancer Institute, and the American Lebanese Syrian Associated Charities. The researchers reported having no conflicts of interest.

Recommended Reading

First reported case of induced resistance to tisagenlecleucel
MDedge Hematology and Oncology
Venetoclax promising in unfit elderly AML patients
MDedge Hematology and Oncology
Novel options for treating hairy cell leukemia
MDedge Hematology and Oncology
Some mutation testing can be useful at CLL diagnosis
MDedge Hematology and Oncology
Genomic profiling predicts outcomes in patients with MPN
MDedge Hematology and Oncology
Optimizing use of TKIs in CML
MDedge Hematology and Oncology
Phase 1 NHL, ALL trials placed on clinical hold
MDedge Hematology and Oncology
CDK8 inhibitor can fight AML, though it’s unclear how
MDedge Hematology and Oncology
Weighing the costs of CAR T-cell therapy
MDedge Hematology and Oncology
Single leukemic cell can contaminate CAR T-cell product
MDedge Hematology and Oncology